Zheng Hu

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Venues

Communications biology

OncoTargets and therapy

Molecular biotechnology

Cell & bioscience

Departments of Clinical Pharmacology, Xiangya Hospital and Institute of Clinical Pharmacology, Central South University

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Departments of Clinical Pharmacology, Xiangya Hospital and Institute of Clinical Pharmacology, Central South University Feb 11 2015

China

postdoctor :: Departments of Clinical Pharmacology, Xiangya Hospital and Institute of Clinical Pharmacology

Translational Medicine Institute, National & Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, the First People’s Hospital of Chenzhou Oct 01 2014

China

Investigator :: Translational Medicine Institute

Education History

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Aug 01 2011 - Jul 01 2014

China

PHD :: South China Institute for Stem Cell Biology and Regenerative Medicine

Publications

Li Wang, Xiaosha Wen, Yang Yang, Zheng Hu, Jing Jiang, Lili Duan, Xiaofen Liao, Yan He, Yaru Liu, Jing Wang, Zhikun Liang, Xiaoya Zhu, Quan Liu, Tian-Cai Liu, Dixian Luo
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma. Communications biology 7 (1) (2024)
Li Wang, Xiaosha Wen, Yang Yang, Zheng Hu, Jing Jiang, Lili Duan, Xiaofen Liao, Yan He, Yaru Liu, Jing Wang, Zhikun Liang, Xiaoya Zhu, Quan Liu, Tian-Cai Liu, Dixian Luo
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma. Communications biology 7 (1) (2024)
Li Wang, Xiaosha Wen, Yang Yang, Zheng Hu, Jing Jiang, Lili Duan, Xiaofen Liao, Yan He, Yaru Liu, Jing Wang, Zhikun Liang, Xiaoya Zhu, Quan Liu, Tian-Cai Liu, Dixian Luo
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma. Communications biology 7 (1) (2024)
Li Wang, Xiaosha Wen, Yang Yang, Zheng Hu, Jing Jiang, Lili Duan, Xiaofen Liao, Yan He, Yaru Liu, Jing Wang, Zhikun Liang, Xiaoya Zhu, Quan Liu, Tian-Cai Liu, Dixian Luo
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma. Communications biology 7 (1) (2024)
Jiayao Qu, Yali Xie, Zhaoyi Guo, Xiangting Liu, Jing Jiang, Ting Chen, Kai Li, Zheng Hu, Dixian Luo
Identification of a Novel Cleavage Site and Confirmation of the Effectiveness of NgAgo Gene Editing on RNA Targets. Molecular biotechnology 63 (12) (2021)
Yanlan Li, Xiangning Li, Jiayao Qu, Dixian Luo, Zheng Hu
Cas9 Mediated Correction of β-catenin Mutation and Restoring the Expression of Protein Phosphorylation in Colon Cancer HCT-116 Cells Decrease Cell Proliferation in vitro and Hamper Tumor Growth in Mice in vivo. OncoTargets and therapy 13 (2020)
Zheng Hu, Li Wang, Zhaoying Shi, Jing Jiang, Xiangning Li, Yonglong Chen, Kai Li, Dixian Luo
Customized one-step preparation of sgRNA transcription templates via overlapping PCR Using short primers and its application in vitro and in vivo gene editing. Cell & bioscience 9 (2019)

Zheng Hu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zheng Hu